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Enhanced Response to Ozone Exposure during
the Follicular Phase of the Menstrual Cycle
Susan D. Fox,' William C. Adams,1 Katherine A. Brookes,1 and Bill L.
Lasley2
IHuman Performance Laboratory, Department of Physical Education and 2Department of
Reproduction, School of Veterinary Medicine, University of California, Davis, CA 95616
USA
Acute ozone (03) exposure has been shown
to result in short-term airway inflammation
in both animals and humans (1,2). This
inflammatory response involves both the
infiltration of neutrophils (1-3) and the
release of cyclooxygenase products from
arachidonic acid in the lung and airways
(3). Seltzer et al. (3) observed significant
increases in the concentrations of pro-
staglandins E2, F2a, and thromboxane B2(cyclooxygenase products) in bronchoalveo-
lar lavage fluid after exposure to 03. In
addition, prostaglandins E2 and F2a appear
to stimulate pulmonary neural afferents ini-
tiating tachypnea and cough, which are
responses characteristic of acute 03 expo-
sure (4,5). Further, Schelegle et al. (6)
found that pretreatment with indometh-
acin, a nonsteroidal anti-inflammatory
drug, significantly attenuated 03-induced
decrements in forced vital capacity (FVC)
and forced expiratory volume in 1 sec
(FEV1). These findings imply that the
release of prostaglandins and subsequent
inflammation in the lung and airways con-
sequent to acute 03 exposure are involved
in routinely observed pulmonary function
decrements.
Progesterone inhibits prostaglandin
production in the uterine endometrium,
though this inhibition fluctuates with the
variant changes in progesterone concentra-
tion observed throughout the female's men-
strual cycle (7,8). If cyclical changes in
steroidal hormones alter a woman's re-
sponse to uterine inflammation, could fluc-
tuations in these hormone levels alter indi-
vidual responses to a known respiratory
inflammatory inducer (viz, 03)? A hy-
pothesis not yet investigated is that expo-
sure to 03 during the follicular (F) men-
strual cyde phase, when progesterone levels
are at their lowest, might result in enhanced
responses due to the absence of anti-inflam-
matory influences of this steroid. The pur-
pose of this study was to determine if
young, adult females respond differentially
to 03 inhalation with respect to menstrual
cycle phase and progesterone concentration.
To investigate this hypothesis, healthy,
young, adult females were exposed to 0 in
the F and mid-luteal (ML) phases of tLeir
menstrual cycles.
Nine healthy, young, adult females,
who participated in recreational aerobic
exercise on a regular basis, served as sub-
jects. We screened each woman for dini-
cally normal pulmonary function, absence
of significant allergies, abstention from tak-
ing birth control pills, and normal menstru-
al function [intermenstrual interval of
greater than 26 days, with sustained rise of
pregnanediol-3-glucuronide (PdG) greater
than 3 pg/mg creatinine for more than 4
days during the luteal phase]. All subjects
were nonsmokers and had not resided in an
area of high air pollution within the previ-
ous 6 months.
Before initiating experimental proto-
cols, each subject completed an orientation
session in which baseline pulmonary func-
tion was obtained and specific equipment
and requirements of the study were re-
viewed. We informed subjects of the pur-
pose, procedures, and potential risks of
participation in the study before they
signed an informed consent form approved
by the University of California's Human
Subjects Review Committee. After com-
pleting the experimental protocols, we
assessed basic anthropometry, including
body composition determination via hy-
drostatic weighing, and maximum oxygen
uptake (VO max). These results are pre-
sented in Table 1.
We studied subjects throughout two to
four complete (though not necessarily con-
secutive) menstrual cycles. Early morning
urine samples (3 ml) were collected
throughout the study period and analyzed
for estrone conjugates (E1C) and PdG
(which were both indexed by creatinine
concentrations of the same sample to adjust
for variations in urine volume) to document
Table 1. Group anthropometric, V02max, and pulmonary function data
Height
(cm)
165.4±4.9
160.0
175.3
Weight Fat V02max V max
(kg) (% body wt) (mVkg/min) (I/min)
64.5±8.3 26.2±4.7 45.3±4.2 111.4±17.9
52.1 19.2 40.9 84.7
78.8 34.1 54.7 140.6
FVC
(I)
4.0±0.44
3.2
4.7
FEV1(I)
3.4±0.46
2.9
4.4
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a normal hormonal profile. We random-
ized subjects and exposed them to either fil-
tered air or 0.30 ppm 03 in the F and ML
phases of ovulatory menstrual cydes. With
day 0 representing the day of the periovula-
tory estrone conjugate peak, the F phase was
determined to be days -6 through the first
Address correspondence to W. C. Adams, Depart-
ment of Physical Education, University of Califor-
nia, Davis, CA 95616 USA. This study was sup-
ported by the State of California Air Resources
Board (Interagency Agreement A933-096) and by
the Superfund Basic Research Program
(P42ES04699). The authors gratefully acknowl-
edge the technical assistance of Richard Fadling,
the laboratory assistance of Robin Looft, Tara
McKittrick, and Kerri Winters, and Susan
Shideler, who contributed help with ovarian hor-
mone analysis and data interpretation. Sincere
appreciation is extended to the subjects for their
contribution of considerable time and effort.
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Means ± SD
Minimum
Maximum
Age
(years)
26.9±5.3
20
34
Abbreviations: V02max, maximum 0 uptake; VEmax, maximum minute ventilation; BTPS, body tempera-
ture, pressure, saturated; FVC, forceWvital capacity; FEV1, forced expiratory volume in 1 sec.
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day of menses. The ML phase was similarly
calculated as day +5 to +10. The exposure
protocol consisted of exercise work rates
such that ventilation minute volume (VE)
was about 50 1/min BTPS (body tempera-
ture, pressure, saturated). The group mean
total inhaled dose of 03 during the 0.30
ppm 03 exposures did not differ significant-
ly between the F (859.9 ppm-1) and ML
(855.6 ppm-1) phases. We conducted all
exposures in a moderate ambient environ-
ment with constant airflow provided from a
floor fan. Subjects were not told whether
they received 03.
We obtained pulmonary function mea-
surements immediately before and after
each experimental protocol. At least two
repeated maneuvers of forced expiration
after maximal inspiration were obtained
using a Collins Modular office spirometer
(model 3000). An on-line data acquisition
system, which interfaced the spirometer
module linear potentiometer output volt-
age (associated with lung volume changes)
and an analog-to-digital converter for read-
ing into a Digital Equipment Corp. LSI
11/2 microcomputer, was also used. Pul-
monary function on-line computer deter-
minations included measurements of FVC,
FEV1, and forced expiratory flow between
25 and 75% of FVC (FEF2,-75). In addi-
tion, we monitored VE and heart rate dur-
ing each protocol.
Subjects inhaled air mixtures during
experimental protocols via a blow-by oblig-
atory mouthpiece system, described in
detail previously (9). Inspiratory 03 con-
centrations in the mixing chamber were
monitored continuously by samples drawn
through 0.64-cm inner diameter Teflon
tubing connected to a Dasibi 03 meter.
The digital reading of 03 concentration in
ppm was compared periodically with that
determined by the ultraviolet absorption
photometric method (10).
After the orientation session, subjects
initiated daily urine collection upon the
first day of menses of a new cycle. Subjects
placed urine samples (3 ml) in a home
freezer after collection and brought them
to the laboratory freezer upon the comple-
tion of a full cycle. The urinary metabo-
lites of the two major ovarian steroid hor-
mones, estrogen and progesterone, were
assessed by enzyme immunoassay (EIA) at
the Institute of Toxicologic and Environ-
mental Health Research, University of
California, Davis, to monitor ovarian func-
tion. The competitive, microtiter plate
solid-phase EIA procedure for the mea-
surement of ElConj and PdG is described
in detail by Munro and colleagues (11).
Urinary hormone concentrations are
expressed as nanogram (ElC) or micro-
gram (PdG) per milligram creatinine.
FVC, FEV1, and FEF25-75 preexposure
values were subtracted from their respective
post-exposure values and then divided by
the preexposure values to obtain percent
changes representing the treatment effect
for each protocol. We analyzed all data via
a two-way analysis of variance (ANOVA)
with repeated measures (12), which tested
for gas concentration effects (filtered air
versus 03 comparison), menstrual phase
effects (F versus ML), and the interaction
between menstrual phase and gas concen-
tration effects. Upon obtaining a signifi-
cant F ratio for main effects as the result of
either gas concentration, menstrual phase,
or their interaction, a paired-t post-hoc test
with modified Bonferroni correction (13)
was applied to determine which particular
mean values were significantly different
from others. Statistical significance was
accepted at the p <0.05 level.
Group mean preexposure and post-
exposure data for pulmonary function para-
meters are presented in Table 2. Specific
significant mean differences obtained by
ANOVA and post hoc procedures are also
included. Post hoc analysis revealed signifi-
cant gas concentration effects (filtered air
versus 0 ) for FVC, FEV1, and FEF2575
and significant gas concentration and men-
strual phase interaction effects for FEV1
and FEF25575 The group mean percent
changes for FEVI for each experimental
protocol are illustrated in Figure 1. The
FEVI decrement of -18.1% observed in the
F phase was significantly greater than the
-13.1% mean value for the ML phase.
This increased effect, which was not ob-
served even as a trend for the filtered air
exposures (Fig. 1), demonstrates the inter-
action of03 and cycle phase.
Whereas the present data are not suffi-
cient to define the cellular mechanisms
involved, they suggest that ovarian steroids
(particularly progesterone) may act to
modulate 03-induced inflammation
occurring in lung tissue. This association
is derived from the observation that the
sensitivity of the lung to ambient 03 is
variable within the same woman and
appears to depend on the phases of her
menstrual cycle. Although most of the
subjects exhibited sensitivity to 03 in both
phases, in general, normally menstruating
women appeared to be more sensitive to
the adverse effects of 03 during the F
phase (low progesterone) compared to the
ML phase (high progesterone) of their
cycle.
All menstrual cycles used in the data
analysis were characterized by low, unvary-
ing PdG concentrations in the F phase,
which were 0.9 ± 0.4 and 1.2 ± 1.4 jig/mg
creatine on the days of the F phase for air
and 03 exposures, respectively. In con-
trast, the PdG concentrations rose 1-2
days after a pronounced mid-cycle ElC
peak and then declined before the next
menstrual period 10-12 days later. The
PdG values on the day of the ML phase
filtered air and 03 protocols (8.6 ± 5.7
and 8.5 ± 6.7 pg/mg creatine, respectively)
were significantly elevated (p<0.0001)
over F-phase levels. There were no signifi-
cant differences between the treatment
groups in mean cycle length, F-phase
length, luteal phase length, or urinary hor-
mone concentrations.
Acute 03 exposure has been shown to
result in the production of inflammatory
mediators (prostaglandins and thrombox-
ane) in the lungs, airways, and plasma of
both animals and humans (2,3,14). Avail-
able data indicate that 03-induced
changes in pulmonary function are the
result of prostaglandin stimulation of
neural afferents in exposed airways (15,16).
In the present study, decreases in FEV1
and FEF25-75 varied significantly with
respect to menstrual cycle phases, which
suggests that there might be some fluctua-
tion in the release or inhibition of pro-
staglandins during the F and ML phases of
the menstrual cycle.
Table 2. Group pre- and post-exposure values for pulmonary function
Filtered air 0.30 03
F (1) ML (2) F (3) ML (4)
Parameter Pre Post Pre Post Pre Post Pre Post Specific mean differences
FVC (1) 3.91 ± 0.40 3.93 ±0.44 4.01 ± 0.45 4.00 ± 0.43 3.90 ±0.53 3.44 ± 0.72 3.99 ± 0.44 3.56 ± 0.58 11-3, 1-4, 2-3, 2-4
FEVJ (1) 3.36 ± 0.41 3.40 ±0.44 3.45 ±0.46 3.51 ± 0.41 3.41 ± 0.50 2.82 ± 0.67 3.42 ± 0.48 2.99 ± 0.55 1-3, 1-4, 2-3, 2-4, 3-4
FEF27, (1/sec) 3.90 ±0.93 3.97 ±0.96 3.99 ±11.0 4.10 ±0.86 4.08 ±0.93 3.14 ±0.96 3.94 ±1.0 3.32 ±0.99 1-3,11-4, 2-3,2-4,3-4
Abbreviations: F, follicular phase; ML, mid-luteal phase; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; FEF 25-7, forced expiratory flowbetween 25 and 75% of FVC. Values are means ± SD. Numbers in parentheses represent protocol number. Percent change values for each protocol [(post-
pre)/(pre) x 1001 were used for statistical comparison to obtain specific mean differences (all significant at p<0.05).
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Figure. 1. Group mean percent change in forced expiratory volume in 1 sec (FEV,) on exposure to filtered
air and to 0.30 ppm 03 in the follicular (F) and mid-luteal (ML) menstrual phases. The mean difference
between the two 0.30-ppm 03 exposures was statistically significant (p< 0.05).
In normally menstruating females,
gonadal steroid hormones are produced at
varying rates during the menstrual cycle.
The F phase is characterized by baseline
progesterone concentrations and increasing
levels of estrogen up until ovulation. After
ovulation, the luteal or secretory phase is
characterized by increasing levels of proges-
terone. Progesterone secretion from the
corpus luteum reaches a peak approximate-
ly 8 days after ovulation and is maintained
for several days (17). Estrogen declines
dramatically after ovulation and then again
rises to moderate levels during the ML
phase. Both progesterone and estrogen
levels decrease at the end of a cycle, thus
triggering menstruation (17).
It has been demonstrated in numerous
studies that sex steroids, essentially estro-
gens and progesterone, exert a significant
effect on prostaglandin synthesis in various
tissues (7,8,18-20). In most cases, estradi-
ol has been found to enhance the synthesis
of prostaglandins E2 and F2a1 whereas
progesterone inhibits their secretion. Kelly
and Smith (8) found that progesterone
reduces prostaglandin F production by
93-96% in human proliferative-phase
endometrium cultured for 2 to 3 days.
The increased FEV1 and FEF25-75 03
responsiveness during the F phase could be
the result of progesterone interaction with
03-induced prostaglandin synthesis. Pro-
gesterone is evident in circulating serum
and plasma samples in concentrations pro-
portional to those observed in uterine tis-
sues (11) and therefore can be found in
respiratory blood flow. During the F
phase of the menstrual cycle, when proges-
terone is low, there may be no inhibition
of prostaglandin synthesis after 03 expo-
sure. In contrast, with higher concentra-
tions of progesterone during the ML
phase, there may be some inhibition of
prostaglandin activity associated with a
concomitant decrease in inflammation,
which results in slightly smaller decrements
in FEV1. Although the involvement of
progesterone in modulating 03-induced
production of prostaglandins is only sug-
gestive, it is the only cyclic hormone that
fits the profile required to have this effect
(i.e., high in the ML and low in the F
phases). However, additional investigation
is warranted in which the role of proges-
terone (and other hormones) can be direct-
ly evaluated, for example, by adding prog-
esterone to an exposed system.
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